Alicia C Olivo has sold NEO and made no open-market buys since Nov 2023

Alicia C. “Ali” Olivo is a corporate attorney and executive who serves as Executive Vice President, General Counsel and Business Development at NeoGenomics, Inc. (NeoGenomics Laboratories), a leading cancer diagnostics company.( She has held the EVP, General Counsel & Business Development role since January 1, 2024 and brings more than 15 years of experience in corporate business, mergers and acquisitions, and legal matters, including significant work in regulatory, fundraising, governance, and transactional activities for NeoGenomics.( As a corporate insider, she has reported multiple equity-related transactions in NeoGenomics stock, including RSU conversions and share disposals in her capacity as EVP, GC & Business Development.(

Olivo joined NeoGenomics in 2019 as Assistant General Counsel, later serving as Interim General Counsel, Deputy General Counsel, and then General Counsel & Corporate Secretary before her promotion to Executive Vice President.( Prior to NeoGenomics, she was a Director at PricewaterhouseCoopers LLP, where she negotiated incentives for numerous Fortune 500 clients, and previously held various roles of increasing responsibility at General Electric, including Counsel overseeing incentives negotiations, tax controversy, and government affairs.( She holds a Bachelor’s degree from the University of Florida and a Juris Doctor from Marquette University Law School, and is licensed as an attorney in Florida.(

Written by Perplexity from public sources.